IDENTIFIKASI GEJALA PASCA VAKSINASI COVID-19 DOSIS KE-3 (BOOSTER)

Penulis

  • Retno Sumara

DOI:

https://doi.org/10.30651/jkm.v0i0.17873

Kata Kunci:

COVID-19 Booster Dose Vaccine, KIPI

Abstrak

Objective:. COVID-19 is a type of disease that infects the human respiratory tract. Transmission of the COVID-19 virus is fast and aggressive. Vaccination is one of the preventive measures that is of concern to inhibit the spread of Covid-19. Booster doses of vaccination are carried out to maintain the effectiveness of the vaccine. AEFI is any medical event that is not expected to occur after immunization where the events are varied, because everyone experiences different symptoms. .

Methods: The research design used a quantitative descriptive study with a population of 211 students and a sample of 138 using a purposive sampling technique. Data analysis using descriptive analytic.

Results: The results showed that the AEFI symptoms that often appeared after the AstraZeneca, Moderna, Pfizer, and Sinovac booster doses of vaccination were Headache, Fever, Pain accompanied by weakness at the injection site, Muscle aches, Swelling at the injection site, Lethargy, Weakness/numbness throughout the body, Weakness on the muscles of the arms and legs, Cough/runny nose, other symptoms (local rash (swelling/red/itchy) on: skin, lips and eyes).

Conclusion: KIPI is an effect caused after vaccination. By knowing these symptoms, it is hoped that the community can prevent and prepare for appropriate management in dealing with KIPI.

Referensi

Chansaenroj, J., Suntronwong, N., Kanokudom, S., Assawakosri, S., Yorsaeng, R., Vichaiwattana, P., Klinfueng, S., Wongsrisang, L., Srimuan, D., & Thatsanatorn, T. (2022). Immunogenicity following two doses of the BBIBP-CorV vaccine and a third booster dose with a viral vector and mRNA COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of the BBIBP-CorV vaccine. Vaccines, 10(7), 1071.

García-Botella, A., García-Lledó, A., Gómez- Pavón, J., Del Castillo, J. G., Hernández- Sampelayo, T., Martín-Delgado, M. C., Sánchez, F. J. M., Martínez-Sellés, M., García, J. M. M., Guillén, S. M., Rodríguez-Artalejo, F., Ruiz-Galiana, J., Cantón, R., Ramos, P. D. L., & Bouza, E. (2022). Booster or additional vaccination doses in patients vaccinated against COVID-19. Revista Espanola de Quimioterapia, 35(2), 105–114. https://doi.org/10.37201/req/149.2021

Hafizzanovian, H., Oktariana, D., Apriansyah, M. A., & Yuniza, Y. (2021). Peluang Terjadinya Immunization Stress-Related Response (Isrr) Selama Program Vaksinasi Covid-19. Jurnal Kedokteran Dan Kesehatan Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya, 8(3), 211–222. https://doi.org/10.32539/jkk.v8i3.13807

Hidayat, R., Mustika, A. P., Avisha, F., Djuliannisaa, Z., Winari, D. D., Putri, R. A., Lisman, H. M., Davin, V., Widhani, A., Aini, M. H., Rahmadani, M., Istanti, N. D., & Giantini, A. (2022). Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA- Based V accine in Universitas Indonesia Hospital Health Personnel. Vaccines, 10(6), 1– 10. https://doi.org/10.3390/vaccines10060877

Kadali, R. A. K., Janagama, R., Peruru, S., & Malayala, S. V. (2021). Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed

self-reported symptoms from healthcare workers. International Journal of Infectious Diseases, 106(2001), 376–381. https://doi.org/10.1016/j.ijid.2021.04.047

Kemenkes. (2022). Triwulan 1 Vaksin Booster Fokus Gunakan AstraZeneca.

Kementerian Kesehatan Republik Indonesia. (2021). Kejadian Ikutan Paska Imunisasi (KIPI) Pada Vaksinasi COVID-19.

Kesehatan, K. (2021). Question ( Faq ) Pelaksanaan Vaksinasi Covid-. Kesmas, 2(1), 1–16.

Kesehatan, K. (2022a). Informasi Tentang KIPI atau Reaksi Setelah Vaksinasi COVID-19.

Kesehatan, K. (2022b). V aksinasi COVID-19 Nasional.

McCartney, P. R. (2020). Sex-based vaccine response in the context of COVID-19. Journal of Obstetric, Gynecologic, and Neonatal Nursing, 49(5), 405.

Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., ... Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, 21(7), 939–949. https://doi.org/10.1016/S1473-3099(21)00224- 3

Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021). COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and moderna vaccines. European Review for Medical and Pharmacological Sciences, 25(3), 1663–1679. https://doi.org/10.26355/eurrev_202102_24877

Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., ... Appleby, K. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet, 398(10318), 2258– 2276. https://doi.org/10.1016/S0140-

Jurnal Keperawatan Muhammadiyah Edisi Khusus ICHIT 2023

(21)02717-3

Pratama, A. R. L., Magglin, C., Jufrie, H., Arviana, N. L., Fatimah, N., Nuryanto, M. K., Bakhtiar, R., & Opiansyah, O. (2022). KARAKTERISTIK KEJADIAN IKUTAN PASCA IMUNISASI MODERNA PADA TENAGA KESEHATAN DI SAMARINDA. Jurnal Kedokteran Mulawarman, 9(1), 1–13.

Seyed Hosseini, E., Riahi Kashani, N., Nikzad, H., Azadbakht, J., Hassani Bafrani, H., & Haddad Kashani, H. (2020). The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology, 551(September), 1–9. https://doi.org/10.1016/j.virol.2020.08.011

Sultana, A., Shahriar, S., Tahsin, M. R., Mim, S. R., Fatema, K. R., Saha, A., Yesmin, F., Bahar, N. B., Samodder, M., Mamun, M. A. H., Rahman, M. A., Ferdousy, S., Akter, T., Aktar, F., Kuddus, M. R., Rahman, M. M., Sarker, M. M. R., Büyüker, S. M., Chowdhury, J. A., ... Amran, M. S. (2021). A retrospective cross- sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh. Vaccines, 9(10), 1–10. https://doi.org/10.3390/vaccines9101090

Yulyani, V., Hasbie, N. F., Farich, A., & Valentine, A. (2022). Hubungan Status Demografi, Komorbid Dengan KIPI Post Vaksin COVID- 19 Pada Tenaga Kesehatan. Jurnal Ilmiah Kesehatan Sandi Husada, 11, 153–160. https://doi.org/10.35816/jiskh.v11i1.725

Unduhan

Diterbitkan

2023-01-31

Terbitan

Edisi Khusus (2023): International Conference of Health Innovation and Technology (ICHIT)

Bagian

Full Artikel

Lisensi

    1. Penulis tetap memegang hak atas karyanya dan memberikan hak publikasi pertama kepada jurnal ini yang secara simultan karya tersebut dilisensikan di bawah: Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0)